DBV Technologies has entered into a collaboration agreement with BioNet-Asia Co. and the University of Geneva (UNIGE) to develop a whooping cough (pertussis) booster vaccine. The clinical proof-of-concept product candidate will combine BioNet’s recombinant non-toxic Pertussis Toxin (rPT) with DBV’s Viaskin technology, which allows for the epicutaneous delivery of the antigen without an adjuvant. The R&D collaboration will measure the specific immunity and protective responses el...